Program
Fluorouracil
Also written as “5-Fluorouracil”, “fluorouracil” and “5-fluorouracil”.
Its studies are mostly in Colorectal Neoplasms · Pancreatic Neoplasms · Neoplasms · Head and Neck Neoplasms · Stomach Neoplasms, led by 12 companies.
Drug pageFluorouracil: every studyMany companies study it; this page follows only the 34 they lead. All 763 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 160 open or running | phase 4since Sep 14, 2006 | Jan 6, 2001 | none ahead |
| Pfizerits history only | 51 open or running | phase 3since Jan 28, 2000 | Jan 28, 2000 | none ahead |
| Jiangsu HengRui Medicineits history only | 21 open or running | phase 3since Feb 20, 2023 | Mar 8, 2021 | none ahead |
| Otsukaits history only | 20 open or running | phase 3since Jun 2, 2000 | Jun 2, 2000 | none ahead |
| Prologue Research Internationalits history only | 20 open or running | phase 3since Jun 5, 2003 | May 6, 2001 | none ahead |
| Almirallits history only | 10 open or running | phase 3since Nov 10, 2014 | Nov 10, 2014 | none ahead |
| CbsBioscienceits history only | 10 open or running | phase 2since Nov 10, 2016 | Nov 10, 2016 | none ahead |
| Encube Ethicals Pvt.its history only | 10 open or running | phase 3since Sep 23, 2021 | Sep 23, 2021 | none ahead |
| HealthCare Global Enterpriseits history only | 10 open or running | phase 2since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Feb 25, 2019 | Feb 25, 2019 | none ahead |
| Sol-Gel Technologiesits history only | 10 open or running | phase 3since Oct 30, 2018 | Oct 30, 2018 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Nov 25, 2015 | Nov 25, 2015 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, Parexel, Halozyme Therapeutics, BioLineRx, Baili-Bio (Chengdu) Pharmaceutical, Quintiles, Takeda, Almirall Hermal and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Jan 28, 2000.
- Jan 28, 20083 phase 2 studiesSanofi · NCT00612495, NCT00611754, NCT00611507
- Oct 28, 2008Phase 2 study in Uterine NeoplasmsSanofi · NCT00782041 · 11 enrolled · Thailand
- Sep 22, 2009Phase 3 study in Head and Neck NeoplasmsSanofi · NCT00995293 · 240 enrolled · China
- Aug 14, 2013Phase 1 study in NeoplasmsSanofi · NCT01930552 · 20 enrolled · China
- Nov 10, 2014Almirall’s first study: phase 3 study in Keratosis, ActinicNew to AlmirallAlmirall · NCT02289768 · 166 enrolled · Germany, United Kingdom
- Nov 25, 2015Teva Pharmaceutical Industries’ first study: phase 3 study in Keratosis, ActinicNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT02616601 · 422 enrolled · United States
- Sep 29, 2016HealthCare Global Enterprise’s first study: phase 2 study in Tongue NeoplasmsNew to HealthCare Global EnterpriseHealthCare Global Enterprise · NCT02985255 · 30 enrolled · India
- Nov 10, 2016CbsBioscience’s first study: phase 2 study in Hepatocellular Carcinoma Non-ResectableNew to CbsBioscienceCbsBioscience · NCT02967887 · 96 enrolled · Korea, Republic of
- Oct 30, 2018Sol-Gel Technologies’ first study: phase 3 study in Keratosis, ActinicNew to Sol-Gel TechnologiesSol-Gel Technologies · NCT03727074 · 462 enrolled · United States
- Feb 25, 2019Sino Biopharmaceutical’s first study: phase 3 study in Squamous Cell Carcinoma of Head and NeckNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03855384 · 334 enrolled · China
- Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
- Mar 8, 2021Jiangsu HengRui Medicine’s first study: phase 1 study in Advanced Pancreatic CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04796948 · 41 enrolled · China
- Sep 23, 2021Encube Ethicals Pvt.’s first study: phase 3 study in Keratosis, ActinicNew to Encube Ethicals Pvt.Encube Ethicals Pvt. · NCT05078827 · 458 enrolled · United States
- Feb 20, 2023Phase 3 study in First-line Treatment of Advanced Pancreatic CancerJiangsu HengRui Medicine · NCT05751850 · 778 planned · China
TargetBeta
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule
Other programs on TYMS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| Capecitabinerule | Hoffmann-La Roche | phase 4 | 129 |
| Tegafurrule | Otsuka | phase 3 | 25 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05751850First-line Treatment of Advanced Pancreatic Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 30, 2024 | 778 |
| NCT05078827Keratosis, Actinic · United States | 3 | Completed | Encube Ethicals Pvt. | Nov 1, 2022 | 458 |
| NCT04796948Advanced Pancreatic Cancer · China | 1 | Completed | Jiangsu HengRui Medicine | Jun 28, 2024 | 41 |
| NCT04607421Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Mar 1, 2025 | 841 |
| NCT03855384Squamous Cell Carcinoma of Head and Neck · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 31, 2020 | 334 |
| NCT03727074Keratosis, Actinic · United States | 3 | Completed | Sol-Gel Technologies | Dec 19, 2019 | 462 |
| NCT02967887Hepatocellular Carcinoma Non-Resectable · Korea, Republic of | 2 | UNKNOWN | CbsBioscience | Oct 2018 | 96 |
| NCT02985255Tongue Neoplasms · India | 2 | UNKNOWN | HealthCare Global Enterprise | Jun 2017 | 30 |
| NCT02616601Keratosis, Actinic · United States | 3 | Completed | Teva Pharmaceutical Industries | Sep 17, 2015 | 422 |
| NCT02289768Keratosis, Actinic · Germany, United Kingdom | 3 | Completed | Almirall | Sep 2015 | 166 |
| NCT01930552Neoplasms · China | 1 | Completed | Sanofi | Dec 2014 | 20 |
| NCT00995293Head and Neck Neoplasms · China | 3 | Completed | Sanofi | Jan 26, 2018 | 240 |
| NCT00782041Uterine Neoplasms · Thailand | 2 | Terminated | Sanofi | Aug 2003 | 11 |
| NCT00612495Endometrial Neoplasms · France | 2 | Completed | Sanofi | 31 | |
| NCT00611754Head and Neck Neoplasms · France | 2 | Completed | Sanofi | 15 | |
| NCT00611507Stomach Neoplasms · Colombia | 2 | Completed | Sanofi | 21 | |
| NCT00559455Carcinoma, Hepatocellular · Korea, Republic of | 2 | Completed | Sanofi | Jan 2010 | 38 |
| NCT00555672Stomach Neoplasms · Spain | 1 | Completed | Pfizer | Dec 2009 | 34 |
| NCT00499850Adenocarcinoma · Australia | 1 | Completed | Sanofi | Jun 2006 | 18 |
| NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more | 3 | Completed | Sanofi | Mar 2010 | 371 |
| NCT00401323Head and Neck Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Jun 2003 | 568 |
| NCT00382720Stomach Neoplasms · United States, Belgium, France and more | 2 | Completed | Sanofi | Apr 2010 | 275 |
| NCT00377273Keratosis, Actinic · United States | 4 | Completed | Sanofi | 250 | |
| NCT00343239Stomach Neoplasms · Turkey | 2 | Completed | Sanofi | Mar 2012 | 59 |
| NCT00261703Head and Neck Neoplasms · Portugal, Spain | 3 | Completed | Sanofi | Jul 2010 | 439 |
| NCT00259402Esophageal Neoplasms · Spain | 2 | Completed | Sanofi | Oct 2008 | 41 |
| NCT00143403Colorectal Neoplasms · Belgium, Denmark, France and more | 3 | Completed | Pfizer | Feb 2008 | 321 |
| NCT00400179Stomach Neoplasms · United States, Canada | 3 | Completed | Otsuka | Mar 2008 | 1,053 |
| NCT00062426Colorectal Neoplasms · United States | 3 | Completed | Prologue Research International | ||
| NCT00026273Colorectal Neoplasms · Austria, Belgium, Egypt and more | 3 | Completed | Pfizer | Sep 2004 | |
| NCT00016198Colorectal Neoplasms · United States | 2 | Completed | Prologue Research International | Apr 2003 | |
| NCT00008281Colorectal Neoplasms · United States, Canada | 3 | UNKNOWN | Sanofi | ||
| NCT00005871Pancreatic Neoplasms · United States | 3 | UNKNOWN | Otsuka | ||
| NCT00004252Colorectal Neoplasms · United States | 3 | Completed | Pfizer | Sep 2007 |
How it is read
Names in the registry
- “5-Fluorouracil”, 10 entries
- “fluorouracil”, 9 entries
- “Fluorouracil”, 8 entries
- “5-fluorouracil”, 7 entries
- “5-FU”, 5 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 18 studies
- Pancreatic Neoplasms, 9 studies
- Neoplasms, 7 studies
- Head and Neck Neoplasms, 7 studies
- Stomach Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.